Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 4/20 | 0.42 |
| ▸ | USP8 | P40818 | 4/20 | 0.42 |
| ▸ | ACLY | P53396 | 3/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30547568 | 1.00 | MEN1 (0.45) | MEN1KMT2AL3MBTL1KDM1AUSP2 | |
| SCHEMBL23877468 | 0.90 | USP2 (0.44) | MEN1KMT2AL3MBTL1KDM1AUSP2 | |
| SCHEMBL31046840 | 0.90 | USP2 (0.44) | MEN1KMT2AL3MBTL1KDM1AUSP2 | |
| SCHEMBL23877535 | 0.84 | KDM1A (0.48) | MEN1KMT2AKDM1AUSP2USP8 | |
| SCHEMBL23879636 | 0.83 | KDM1A (0.50) | MEN1KMT2AL3MBTL1KDM1AUSP2 | |
| SCHEMBL31046884 | 0.83 | KDM1A (0.50) | L3MBTL1KDM1AUSP2USP8ACLY | |
| SCHEMBL23877472 | 0.83 | KDM1A (0.50) | L3MBTL1KDM1AUSP2USP8ACLY | |
| SCHEMBL23877433 | 0.82 | KDM1A (0.49) | KDM1AUSP2USP8ACLYUSP36 | |
| SCHEMBL23877473 | 0.82 | KDM1A (0.49) | L3MBTL1KDM1AUSP2USP8ACLY | |
| SCHEMBL23877479 | 0.82 | KDM1A (0.49) | L3MBTL1KDM1AUSP2USP8ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240409508-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO, INC. | 2024-12-12 | — | — | US | disclosed |
| US-12049439-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| EP-3796975-B1 | SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO INC (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3796975-B1 | SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-02-24 | — | — | US | disclosed |
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | MEN1 1634/4885KMT2A 1234/4885L3MBTL1 4732/4885 |
| US-12049439-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | MEN1 1634/4885KMT2A 1234/4885L3MBTL1 4732/4885 |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | NR3C2, NR5A1, SRD5A2 | MEN1 3346/4885KMT2A 2071/4885L3MBTL1 3102/4885 |
| US-20240409508-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | MEN1 1634/4885KMT2A 1234/4885L3MBTL1 4732/4885 |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | MEN1 1634/4885KMT2A 1234/4885L3MBTL1 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.